ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.2134 ^USD	-3.44%		+3.49%	-14.54%

Jul. 09	ReShape Signs Merger Agreement With Vyome, Asset Sale Deal With Biorad; Shares Rise	MT
Jul. 09	Ninjour Health International Limited agreed to acquire Assets of ReShape Lifesciences Inc for $5.2 million.	CI

Obalon Therapeutics, Inc announced that it has received funding from Amorepacific Ventures.

January 02, 2013 at 11:00 pm EST

Obalon Therapeutics, Inc. announced that it has received funding from a new investor Amorepacific Ventures on January 3, 2013. Roberts Mitani LLC served as an advisor to the investor.

On January 3, 2013, Obalon Therapeutics, Inc closed the transaction.

Latest news about ReShape Lifesciences Inc.

ReShape Signs Merger Agreement With Vyome, Asset Sale Deal With Biorad; Shares Rise	Jul. 09	MT
Ninjour Health International Limited agreed to acquire Assets of ReShape Lifesciences Inc for $5.2 million.	Jul. 08	CI
ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024	May. 15
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	May. 15	MT
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Certain Restricted Stock Units of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Warrants of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Options of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Common Stock of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	Mar. 28	MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	Mar. 28	CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	Feb. 22	CI
Top Midday Gainers	Dec. 13	MT
North American Morning Briefing : Traders Await FOMC, Powell	Dec. 13	DJ
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	Dec. 12	CI
ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band	Dec. 12	DJ
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023	Nov. 09	CI
Transcript : ReShape Lifesciences Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M	Nov. 08	MT
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-29	MT
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29	MT

Chart ReShape Lifesciences Inc.

Duration

Period

More charts

Company Profile

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
RESHAPE LIFESCIENCES INC.	-14.54%	6.27M
THERMO FISHER SCIENTIFIC	+3.26%	209B
DANAHER CORPORATION	+6.55%	183B
INTUITIVE SURGICAL, INC.	+31.66%	158B
BOSTON SCIENTIFIC CORPORATION	+34.32%	114B
SIEMENS HEALTHINEERS AG	+5.13%	67.29B
EDWARDS LIFESCIENCES CORPORATION	+19.33%	54.83B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.88B
AGILENT TECHNOLOGIES, INC.	-4.84%	38.58B
GE HEALTHCARE TECHNOLOGIES INC.	+3.83%	36.65B

Other Advanced Medical Equipment & Technology

ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Obalon Therapeutics, Inc announced that it has received funding from Amorepacific Ventures.

Latest news about ReShape Lifesciences Inc.

Chart ReShape Lifesciences Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology